Market Place
Sourcing Support
BridgeBio to Attend Goldman Sachs Healthcare Conference 2025
02 Jun 2025 //
GLOBENEWSWIRE
Acoramidis Reduces Atrial Fibrillation in ATTR-CM Patients
20 May 2025 //
GLOBENEWSWIRE
Acoramidis Linked to Survival in ATTRibute-CM Study
19 May 2025 //
GLOBENEWSWIRE
BridgeBio Reports Inducement Grants under Nasdaq LR 5635(c)(4)
14 May 2025 //
GLOBENEWSWIRE
First Participant Dosed with Acoramidis in ACT-EARLY Study
13 May 2025 //
GLOBENEWSWIRE
BridgeBio to Share ATTR-CM Data at Heart Congress
12 May 2025 //
GLOBENEWSWIRE
BridgeBio to Join Bank of America Merrill Lynch Healthcare Conf
07 May 2025 //
GLOBENEWSWIRE
BridgeBio`s Attruby has `found a place` in ATTR-CM market: CEO
30 Apr 2025 //
FIERCE PHARMA
BridgeBio reports Q1 2025 financial results and updates
29 Apr 2025 //
GLOBENEWSWIRE
Beyonttra Approved by UK MHRA to Treat ATTR-CM
28 Apr 2025 //
GLOBENEWSWIRE
Purcell & Lefkowitz LLP Investigates BridgeBio Pharma
23 Apr 2025 //
PR NEWSWIRE
BridgeBio to Host Q1 2025 Financial Results Call on April 29
22 Apr 2025 //
GLOBENEWSWIRE
BridgeBio Pharma Reports Inducement Grants under Nasdaq LR 5635(c)(4)
11 Apr 2025 //
GLOBENEWSWIRE
Acoramidis Improves Cardiovascular Outcomes in Variant ATTR-CM
31 Mar 2025 //
GLOBENEWSWIRE
Beyonttra™ (acoramidis) Approved in Japan to Treat ATTR-CM
27 Mar 2025 //
GLOBENEWSWIRE
BridgeBio to Present Cardiovascular Outcomes Data at ACC Sessions
24 Mar 2025 //
GLOBENEWSWIRE
BridgeBio Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
21 Mar 2025 //
GLOBENEWSWIRE
BridgeBio Announces CFO Succession
17 Mar 2025 //
GLOBENEWSWIRE
BBOT & Helix To Merge, Creating Public Oncology Biotech Company
28 Feb 2025 //
BUSINESSWIRE
BridgeBio Prices $500M Notes Due 2031 To Refinance Secured Debt
26 Feb 2025 //
GLOBENEWSWIRE
BridgeBio starts debt management strategy, plans convertible note
24 Feb 2025 //
GLOBENEWSWIRE
BridgeBio Reports Q4, Full-Year 2024 Results & Commercial Update
20 Feb 2025 //
GLOBENEWSWIRE
BridgeBio Pharma to Report Q4 & Full Year 2024 Financial Results
13 Feb 2025 //
GLOBENEWSWIRE
EU Approves BEYONTTRA, A Near-Complete TTR Stabilizer For ATTR-CM
11 Feb 2025 //
GLOBENEWSWIRE
BridgeBio Announce Commercial Progress, Updates, & 2025 Milestones
13 Jan 2025 //
GLOBENEWSWIRE
BridgeBio Gets FDA Fast Track For BBO-8520 In KRAS-Mutated Cancer
09 Jan 2025 //
BUSINESSWIRE
BridgeBio to Participate in J.P. Morgan Healthcare Conference
08 Jan 2025 //
GLOBENEWSWIRE
BridgeBio Oncology to Participate in Morgan Health Conference 2025
23 Dec 2024 //
BUSINESSWIRE
Acoramidis Gets Positive CHMP Nod For ATTR-CM Treatment
13 Dec 2024 //
GLOBENEWSWIRE
Unnatural Products Announces BridgeBio Option for Macrocyclic
03 Dec 2024 //
GLOBENEWSWIRE
BridgeBio Selects PANTHERx® for Attruby™ Distribution
26 Nov 2024 //
PR NEWSWIRE
Orsini Selected by BridgeBio as Pharmacy for ATTRUBY™ Treatment
25 Nov 2024 //
PR NEWSWIRE
Look out, Pfizer: BridgeBio gains `best-case` FDA nod for Attruby
25 Nov 2024 //
FIERCE PHARMA
US FDA approves BridgeBio`s drug for rare heart condition
23 Nov 2024 //
PRESS RELEASE
BridgeBio Oncology Appoints Praveen to its Board of Directors
18 Nov 2024 //
BUSINESSWIRE
BridgeBio Publishes Infigratinib Study for Achondroplasia in NEJM
18 Nov 2024 //
GLOBENEWSWIRE
Acoramidis Shows Sustained Cardiovascular Benefit & Reduce in ACM
18 Nov 2024 //
GLOBENEWSWIRE
BridgeBio touts extension study data for ATTR-CM drug acoramidis
18 Nov 2024 //
FIERCE BIOTECH
BridgeBio Pharma Reports Q3 2024 Financial Results & Update
12 Nov 2024 //
GLOBENEWSWIRE
BridgeBio Oncology Doses First Patient in Phase 1 BREAKER-101 Trial
30 Oct 2024 //
BUSINESSWIRE
BridgeBio Shares Data From CANaspire Study For Canavan Disease
24 Oct 2024 //
GLOBENEWSWIRE
BridgeBio To Show 42-Month Acoramidis Data At AHA 2024
03 Oct 2024 //
GLOBENEWSWIRE
BridgeBio Shares Recurrent Event Analysis Of ATTRibute-CM Study
27 Sep 2024 //
GLOBENEWSWIRE
BridgeBio`s Infigratinib Gets Breakthrough Therapy Status
17 Sep 2024 //
GLOBENEWSWIRE
BridgeBio Reports Phase 1/2 Results For CAH Gene Therapy
10 Sep 2024 //
GLOBENEWSWIRE
BridgeBio`s BBP-812 Receives FDA`s RMAT Designation For Canavan
10 Sep 2024 //
GLOBENEWSWIRE
BridgeBio to stop development of therapy for genetic disorder
10 Sep 2024 //
REUTERS
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
06 Sep 2024 //
GLOBENEWSWIRE
Alnylam shares slide after heart drug data fails to impress investors
30 Aug 2024 //
REUTERS
BridgeBio Shares Data On Serum TTR Increase With Acoramidis
30 Aug 2024 //
GLOBENEWSWIRE
BridgeBio to Present Additional Analyses from ATTRibute-CM Trial at ESC Congress
29 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Pharma to Participate in September Investor Events
28 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Partners with CarDS Lab for AI-Enhanced ATTR-CM Diagnosis
26 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Partners With CarDS Lab To Improve ATTR-CM Diagnosis Using AI
26 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Launches Offshoot With $300M For Genetic Disease Programs
21 Aug 2024 //
FIERCE BIOTECH
BridgeBio Launches MyAchonJourney Resource For Achondroplasia Families
19 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Reports Q2 2024 Results And Business Update
01 Aug 2024 //
GLOBENEWSWIRE
BridgeBio Appoints Thomas Trimarchi As President And COO
23 Jul 2024 //
GLOBENEWSWIRE
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
05 Jul 2024 //
GLOBENEWSWIRE
